Spero Therapeutics
Brian Kane is an accomplished professional in the field of medicinal chemistry and drug development, currently serving as Senior Director and Program Lead at Spero Therapeutics since September 2021. Prior experience includes roles as Associate Director and Project Team Leader at Bristol Myers Squibb and MyoKardia, where Kane led the MYK-224 project and contributed to the discovery of Mavacamten. Previous positions at Portola Pharmaceuticals and as a post-doctoral scholar at the University of California, Berkeley, involved significant contributions to medicinal chemistry projects and the mentoring of interns. Education includes a Post-Doctorate in Chemical Biology from the University of California, Berkeley, a PhD in Medicinal Chemistry from the University of Minnesota, and a BA in Chemistry from Northwestern University.
This person is not in any teams
This person is not in any offices
Spero Therapeutics
2 followers
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections.